Skip to content
  • Products
    About Prospection AI

    A pharma brand's single source for patient-centric intelligence

    Insight

    Track care-and-share with patient-centric leading indicators

    Facility Insights

    Profile accounts and optimize resources with facility-level intelligence

    Journey

    Gain a full understanding of complex patient journeys

    ProGPT

    Refine and explore insights via chat with a handy AI assistant

    Action

    Optimize tactical execution with trigger alerts for events of interest

  • About
    • Technology (PCI Core)
    • Team
    • Careers
    • Contact Us
    • Technology (PCI Core)
    • Team
    • Careers
    • Contact Us
  • Resources
    • All Resources
    • Articles
    • Case Studies
    • Events & News
    • Podcasts & Webinars
    • Publications
    • All Resources
    • Articles
    • Case Studies
    • Events & News
    • Podcasts & Webinars
    • Publications
Request Demo
  • Products
    • About Prospection AI
    • Critical Insights
    • ProGPT
    • Insight
    • Journey
    • Action
  • About
    • Team
    • Careers
    • Contact us
  • Resources
    • All Resources
    • Articles
    • Case Studies
    • Events & news
    • Podcast & webinars
    • Publications
  • English
    • 日本語

Login

Login
  • English

    日本語

Request Demo

Therapeutic Area: Neuroscience

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia

This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.

Antipsychotic prescribing patterns in Australia: a retrospective analysis

This study aimed to examine real-world patterns of antipsychotic use in patients with schizophrenia Australia.

Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia

This study aimed to assess the risks of people on medication for schizophrenia developing different components of the metabolic syndrome and their life expectancy, through reference to a representative population of Australians without schizophrenia.

Helping get the right patients on the right treatment at the right time.

Get in Touch
  • ISO/IEC 27001:2013 | MSECB Certified
  • Copyright 2026 Prospection | All Rights Reserved
  • Privacy Policy
  • ©2026 Prospection | All Rights Reserved
  • ISO/IEC 27001:2013 | MSECB Certified
  • Privacy Policy